Skip to main content
Top
Published in: Advances in Therapy 6/2020

Open Access 01-06-2020 | Beclometasone | Original Research

Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study

Authors: Mounika Parimi, Henrik Svedsater, Quratul Ann, Mugdha Gokhale, Christen M. Gray, David Hinds, Mark Nixon, Naomi Boxall

Published in: Advances in Therapy | Issue 6/2020

Login to get access

Abstract

Introduction

Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use of ICS/LABAs by comparing treatment persistence and adherence among patients with asthma in the United Kingdom initiating fluticasone furoate/vilanterol (FF/VI) versus budesonide/formoterol (BUD/FM) or beclometasone dipropionate/formoterol (BDP/FM).

Methods

A retrospective new-user active comparator database study was conducted in the IQVIA Medical Research Database. Propensity score (PS) matching was performed for FF/VI versus BUD/FM, and FF/VI versus BDP/FM. The primary objective was to compare patient treatment persistence (time to discontinuation), while secondary objectives included assessing adherence (mean proportion of days covered [PDC] with medication in the study period) and the proportions of patients achieving ≥ 50% and ≥ 80% PDC.

Results

New users of FF/VI (N = 966), BUD/FM (N = 5931) and BDP/FM (N = 9607) were identified and PS-matched: FF/VI (n = 945) versus BUD/FM (n = 3272), and FF/VI (n = 902) versus BDP/FM (n = 3465). At 12 months, treatment persistence was 69% (FF/VI), 53% (BUD/FM) and 57% (BDP/FM). The likelihood of treatment discontinuation within 12 months after initiation with FF/VI was 35% lower than with BUD/FM and 31% lower than for BDP/FM (both p < 0.001). Mean PDC was higher for FF/VI compared with BUD/FM (77.7 vs 72.4; p < 0.0001) and BDP/FM (78.2 vs 71.0; p < 0.0001). The odds of achieving ≥ 50% and ≥ 80% PDC were greater for FF/VI than for BUD/FM and BDP/FM.

Conclusions

In this study, patients who initiated FF/VI were less likely to discontinue treatment and showed greater treatment adherence versus patients who initiated BUD/FM or BDP/FM.
Appendix
Available only for authorised users
Literature
3.
go back to reference Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des. 2006;12:3261–79.CrossRef Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des. 2006;12:3261–79.CrossRef
7.
go back to reference Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247–55.CrossRef Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247–55.CrossRef
8.
go back to reference Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56:748–57.CrossRef Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56:748–57.CrossRef
9.
go back to reference Averell CS, Stanford R, Laliberte F, Wu J, Germain G, Duh M. Adherence with once-daily fluticasone furoate/vilanterol compared to twice-daily budesonide/formoterol or fluticasone propionate/salmeterol in asthma. Ann Allergy Asthma Immunol. 2018;121:S39.CrossRef Averell CS, Stanford R, Laliberte F, Wu J, Germain G, Duh M. Adherence with once-daily fluticasone furoate/vilanterol compared to twice-daily budesonide/formoterol or fluticasone propionate/salmeterol in asthma. Ann Allergy Asthma Immunol. 2018;121:S39.CrossRef
10.
go back to reference Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.CrossRef Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.CrossRef
11.
go back to reference Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14.CrossRef Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14.CrossRef
12.
go back to reference Price D, Brusselle G, Roche N, Freeman D, Chisholm A. Real-world research and its importance in respiratory medicine. Breathe. 2015;11:26–38.CrossRef Price D, Brusselle G, Roche N, Freeman D, Chisholm A. Real-world research and its importance in respiratory medicine. Breathe. 2015;11:26–38.CrossRef
13.
go back to reference Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407.CrossRef Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407.CrossRef
14.
go back to reference van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079.CrossRef van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079.CrossRef
15.
go back to reference Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.CrossRef Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.CrossRef
16.
go back to reference Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2(63–72):17. Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2(63–72):17.
18.
go back to reference Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167:492–9.CrossRef Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167:492–9.CrossRef
19.
go back to reference Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2(6):757–64.CrossRef Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2(6):757–64.CrossRef
20.
go back to reference Baumgartner PC, Haynes RB, Arnet I, et al. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.CrossRef Baumgartner PC, Haynes RB, Arnet I, et al. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.CrossRef
24.
go back to reference Boutopoulou B, Koumpagioti D, Matziou V, Priftis KN, Douros K. Interventions on adherence to treatment in children with severe asthma: a systematic review. Front Pediatr. 2018;6:232.CrossRef Boutopoulou B, Koumpagioti D, Matziou V, Priftis KN, Douros K. Interventions on adherence to treatment in children with severe asthma: a systematic review. Front Pediatr. 2018;6:232.CrossRef
25.
26.
go back to reference Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.CrossRef Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.CrossRef
27.
go back to reference Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract. 2008;58:37–433.CrossRef Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract. 2008;58:37–433.CrossRef
28.
go back to reference Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97(1):24–33.CrossRef Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97(1):24–33.CrossRef
30.
go back to reference Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–8.CrossRef Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–8.CrossRef
35.
go back to reference Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting beta-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(1488–96):e7. Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting beta-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(1488–96):e7.
36.
go back to reference Atsuta R, TakaiIsao J, Mukai I, Kobayashi A, Ishii T, Svedsater H. Patients with asthma prescribed once-daily fluticasone furoate/vilanterol or twice-daily fluticasone propionate/salmeterol as maintenance treatment: analysis from a claims database. Pulm Ther. 2018;4:135–47.CrossRef Atsuta R, TakaiIsao J, Mukai I, Kobayashi A, Ishii T, Svedsater H. Patients with asthma prescribed once-daily fluticasone furoate/vilanterol or twice-daily fluticasone propionate/salmeterol as maintenance treatment: analysis from a claims database. Pulm Ther. 2018;4:135–47.CrossRef
Metadata
Title
Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study
Authors
Mounika Parimi
Henrik Svedsater
Quratul Ann
Mugdha Gokhale
Christen M. Gray
David Hinds
Mark Nixon
Naomi Boxall
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01344-8

Other articles of this Issue 6/2020

Advances in Therapy 6/2020 Go to the issue